Company Legal Name
Latest Valuation
Founded Year
Headquarter
Ignis Therapeutics is a Shanghai-based biopharmaceutical company focused on developing innovative therapeutic solutions for central nervous system disorders, with particular emphasis on epilepsy and Parkinson's disease. The company operates in the specialized CNS therapeutics market, addressing significant unmet medical needs in neurological conditions that affect millions of patients worldwide. By concentrating on these complex disorders, Ignis positions itself within a high-barrier therapeutic area that demands sophisticated drug development capabilities and deep neurological expertise. The company continues to advance its pipeline of CNS-targeted therapies, aiming to deliver breakthrough treatments for patients suffering from debilitating neurological conditions.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.
